Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus chemotherapy for first-line recurrent or metastatic nasopharyngeal carcinoma in a non-endemic population
2025-522472-85-00Phase 3Authorised
- Sponsor
- Humanitas Research Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sugemalimab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Humanitas Research Hospital. Primary endpoint: Incidence of high-grade treatment-related adverse events. Planned start Oct 2025; status: authorised.
02
Drugs
sugemalimabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2025-522472-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522472-85-00.